The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials.
biliary tract cancer
cholangiocarcinoma
durvalumab
immune checkpoint inhibitors
immunotherapy
pembrolizumab
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2024
2024
Historique:
received:
19
04
2024
accepted:
26
06
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
We performed a systematic review and meta-analysis to further explore the impact of the addition of immunotherapy to gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancer (BTC) patients. Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine-cisplatin as the new standard first-line treatment for advanced BTC patients. https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.
Sections du résumé
Background
UNASSIGNED
We performed a systematic review and meta-analysis to further explore the impact of the addition of immunotherapy to gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancer (BTC) patients.
Methods
UNASSIGNED
Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator
Results
UNASSIGNED
A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau
Conclusion
UNASSIGNED
The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine-cisplatin as the new standard first-line treatment for advanced BTC patients.
Systematic review registration
UNASSIGNED
https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.
Identifiants
pubmed: 39091909
doi: 10.3389/fonc.2024.1409132
pmc: PMC11291215
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Pagination
1409132Informations de copyright
Copyright © 2024 Vitale, Rizzo, Maistrello, Nardulli, Talienti, Quaresmini, De Summa, Massafra, Silvestris and Brunetti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.